secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0000950170-24-126753
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics Q3 net loss $12.7M; cash $30.4M extended into Q3 2025
-----------------------------------------------------------------------

- Net loss of $12.7M for Q3 2024, compared to $18.3M in Q3 2023; includes $4.1M stock-based comp.
- Cash, equivalents and marketable securities $30.4M as of Sep 30, 2024; runway extended into Q3 2025.
- Completed two equity offerings for total gross proceeds of ~$20.0M in July and October 2024.
- New preclinical PK data supports oral delivery of GLP-1/GIP/glucagon triagonist via RaniPill platform.
- Phase 1 trial of RT-114 (GLP-1/GLP-2 dual agonist) for obesity expected to start in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017024126753/0000950170-24-126753-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017024126753/rani-20241114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-126753

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer